Management of Acutely Symptomatic Hernias (MASH) study
Symptomatic abdominal wall hernias are a common presentation to the emergency surgical team. Results from the NASBO project in 2017 demonstrated that patients presenting with small bowel obstruction secondary to a groin hernia had significantly higher mortality than those with other causative pathologies. At present there is limited evidence for the management of acutely symptomatic abdominal wall or groin hernias and therefore practice varies between and even within hospitals. By establishing the commonly used management strategies and assessing outcomes, we hope to be able to improve the care this group of patients receives.
Management of Acutely Symptomatic Hernias (MASH) is a prospective cohort study which will run for 12 weeks in early 2020. The study is hoping to collate national data from across 50 hospitals, on the inpatient management and 30- and 90-day outcomes including complications and quality of life after treatment of acutely symptomatic hernia. All abdominal wall and groin hernias (other than parastomal, traumatic, diaphragmatic and hiatal) will be eligible for inclusion.
MASH is being run by the White Rose Surgical Collaborative, with support from the Sheffield Clinical Trials Unit and funding from the British Hernia Society. This is a portfolio eligible research project that will give trainees the opportunity to learn the skills required to be a principal investigator. Outcomes of the study will be published using a collaborative authorship model.
We are looking to recruit acute surgical hospitals across the UK to be a part of this exciting project. For further information or to sign your unit up for the study, please click the following link: http://bit.ly/Mash2020 or you can contact us via email (MASHernia@gmail.com) or Twitter (@MASH_2019_)